- 免疫疗法 -
The Immunotherapy stream focuses on the latest science, modalities and targeting strategies driving the development of immunotherapies for solid and liquid tumors. Part One examines strategies for demonstrating T cell activity, combinations, preventing toxicology, dosing, and targeting the tumor microenvironment. Part Two focuses on developing and engineering adoptive cell therapies for solid and liquid tumors, especially CAR Ts, TCRs, NKs, and TILs, as well as new targets of interest. Finally, Part Three examines new clinical and preclinical data in agonist immunotherapy targets, as well as the biology and mechanisms of these emerging therapies of interest. Together, these three units will provide a focused look at how industry is applying new science and technology in developing the next generation of targeted cancer immunotherapies.
Prasad Adusumilli, MD, FACS, FCCPDeputy Chief and Associate Attending, Thoracic Surgery; Director, Mesothelioma
Adrian Bot, PhD Vice President, Translational Medicine, Kite Pharma, a Gilead Company
Axel Hoos, PhD Senior Vice President, Therapeutic Area Head, Oncology, GSK
Jeffrey Miller, MD Professor of Medicine, Deputy Director, Masonic Cancer Center, Division of Hematology, Oncology and Transplantation, University of Minnesota